BG101803A - Use of melatonin for treating patients suffering from drug addiction - Google Patents

Use of melatonin for treating patients suffering from drug addiction

Info

Publication number
BG101803A
BG101803A BG101803A BG10180397A BG101803A BG 101803 A BG101803 A BG 101803A BG 101803 A BG101803 A BG 101803A BG 10180397 A BG10180397 A BG 10180397A BG 101803 A BG101803 A BG 101803A
Authority
BG
Bulgaria
Prior art keywords
melatonin
drug
patient
patients suffering
treating patients
Prior art date
Application number
BG101803A
Other languages
Bulgarian (bg)
Other versions
BG62876B1 (en
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,535 external-priority patent/US6469044B1/en
Application filed by Neurim Pharmaceuticals (1991) Ltd. filed Critical Neurim Pharmaceuticals (1991) Ltd.
Publication of BG101803A publication Critical patent/BG101803A/en
Publication of BG62876B1 publication Critical patent/BG62876B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Melatonin is used in the manufacture of a medicament fortreating a multidrug addict, or a patient who has symptoms ofhaving become dependent on, tolerant of, or addicted to abenzodiazepine drug, or for treating a patient who has beenclinically diagnosed as having a condition susceptible toalleviation by administration of a benzodiazepine drug, whilesimultaneously preventing the occurrence in the patient ofsymptoms of dependence on, tolerance of, or addiction to saidbenzodiazepine drug. The invention further relates to apharmaceutical formulation for the above-stated purposes, whichcomprises at least one diluent, carrier or adjuvant and as activeingredients a benzodiazepine drug and melatonin.9 claims
BG101803A 1995-02-01 1997-07-30 The application of melatonin for the treatment of patients with medicament addiction BG62876B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/381,535 US6469044B1 (en) 1995-02-01 1995-02-01 Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
EP95303853A EP0724878B1 (en) 1995-02-01 1995-06-06 Use of melatonin for treating patients suffering from drug dependencies
PCT/IB1996/000082 WO1996023496A1 (en) 1995-02-01 1996-01-29 Use of melatonin for treating patients suffering from drug addiction

Publications (2)

Publication Number Publication Date
BG101803A true BG101803A (en) 1998-04-30
BG62876B1 BG62876B1 (en) 2000-10-31

Family

ID=26140195

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101803A BG62876B1 (en) 1995-02-01 1997-07-30 The application of melatonin for the treatment of patients with medicament addiction

Country Status (22)

Country Link
JP (1) JP4516159B2 (en)
CN (1) CN1083263C (en)
AT (1) AT408188B (en)
AU (1) AU695366B2 (en)
BG (1) BG62876B1 (en)
BR (1) BR9607169A (en)
CZ (1) CZ291349B6 (en)
DK (1) DK176081B1 (en)
EE (1) EE03384B1 (en)
FI (1) FI119586B (en)
IS (1) IS1980B (en)
LU (1) LU90118B1 (en)
LV (1) LV11940B (en)
MD (1) MD1716C2 (en)
NO (1) NO312814B1 (en)
NZ (1) NZ298878A (en)
PL (1) PL183148B1 (en)
SI (1) SI9620022A (en)
SK (1) SK284521B6 (en)
TR (1) TR199700723T1 (en)
TW (1) TW483757B (en)
WO (1) WO1996023496A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200379A (en) 2000-01-05 2003-10-15 Neurim Pharmaceuticals (1991) Ltd. Method and Preparation for the Treatment of Resistance to Antihypertensive Agents and Related Conditions
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Composition for treating insomnia
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
CN104519877A (en) 2012-01-26 2015-04-15 万达制药公司 Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20150093236A (en) 2012-12-18 2015-08-17 반다 파마슈티칼즈, 인코퍼레이티드. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
LT3337462T (en) * 2016-10-31 2021-01-11 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181670T1 (en) * 1991-05-09 1999-07-15 Neurim Pharma 1991 MEDICINAL PRODUCTS CONTAINING MELATONIN
IT1251544B (en) * 1991-05-13 1995-05-17 Gabriele Biella PHARMACEUTICAL COMPOSITIONS ACTIVE IN THE THERAPY OF SLEEP DISORDERS INCLUDING MELATONIN OR A DERIVATIVE IN ASSOCIATION WITH A BENZODIAZEPINE DERIVATIVE

Also Published As

Publication number Publication date
NO973531D0 (en) 1997-07-31
AU695366B2 (en) 1998-08-13
NO973531L (en) 1997-09-30
IS1980B (en) 2005-01-14
LU90118B1 (en) 1997-11-13
CN1172431A (en) 1998-02-04
FI973185A0 (en) 1997-07-31
DK89697A (en) 1997-07-30
MD970254A (en) 1999-05-31
TR199700723T1 (en) 1998-02-21
BG62876B1 (en) 2000-10-31
TW483757B (en) 2002-04-21
LV11940B (en) 1998-05-20
FI973185A (en) 1997-09-30
JPH10513177A (en) 1998-12-15
JP4516159B2 (en) 2010-08-04
BR9607169A (en) 1997-11-11
NZ298878A (en) 1999-05-28
PL183148B1 (en) 2002-05-31
CZ240597A3 (en) 1998-01-14
ATA901396A (en) 2001-02-15
LV11940A (en) 1998-01-20
CZ291349B6 (en) 2003-02-12
FI119586B (en) 2009-01-15
MD1716B2 (en) 2001-08-31
DK176081B1 (en) 2006-04-18
SK284521B6 (en) 2005-05-05
EE03384B1 (en) 2001-04-16
PL321630A1 (en) 1997-12-08
NO312814B1 (en) 2002-07-08
MX9705856A (en) 1998-07-31
MD1716C2 (en) 2002-02-28
WO1996023496A1 (en) 1996-08-08
AU4457496A (en) 1996-08-21
SK103097A3 (en) 1998-01-14
EE9700166A (en) 1998-02-16
SI9620022A (en) 1998-10-31
IS4532A (en) 1997-07-25
AT408188B (en) 2001-09-25
CN1083263C (en) 2002-04-24

Similar Documents

Publication Publication Date Title
NO306457B1 (en) 2,4-disulfonylphenylbutylnitron, salts thereof, pharmaceutical composition, and the use of this compound in the manufacture of a medicament
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
MY106075A (en) A method of treating anxiety-related disorders using sertraline.
BG101803A (en) Use of melatonin for treating patients suffering from drug addiction
RO116771B1 (en) Method for preventing or treating the addiction on, tolerance or abuse of benzodiazepines
NO308644B1 (en) Use of 4-aminopyridine for the preparation of a pharmaceutical composition
HU9403020D0 (en) Agents for treating substance abuse disorders
WO1996023496B1 (en) Use of melatonin for treating patients suffering from drug addiction
JPS6483020A (en) Medicinal composition for preventing or treating aids
EE9700366A (en) Use of angiotensin type II receptor antagonists in the manufacture of a medicament for the prophylaxis and / or treatment of dyspeptic symptoms and pharmaceutical preparations containing angiotensin type II receptor antagonists
PT862454E (en) NEW USES OF MAMIFERO CTLA-8 AND RELATED REAGENTS
Neill Postoperative analgesia following brachial plexus block
CA2211839A1 (en) Use of melatonin for treating patients suffering from drug addiction
Fink et al. Opiate antagonists in the treatment of heroin dependence
DK0457336T3 (en) New use of 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olate